In NZ, trastuzumab was publicly funded for women with HER2-positive advanced breast cancer from July 2005 and, subsequently, for early breast cancer, initially for 9 weeks from July 2007 and later extended to 12 months from December 2008 [10]. Here, ERBB2 is linked to breast carcinoma.